Effects of Triiodothyronine (T3) in Ischemic Heart Failure
Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This study aims to determine whether giving triiodothyronine (T3), a thyroid hormone, is safe
and helps improve symptoms and signs of heart failure.
The study is divided into 2 phases. In the first phase, participants have a 50-50 chance of
receiving the study drug. Participants who are randomized to receive the study drug will be
admitted to the General Clinical Research Center (GCRC) for 5 days for oral thyroid hormone
treatment and monitoring. They will have 4 additional follow-up visits over the next year.
Participants who are not randomized to receive the study drug will not be admitted but will
have similar follow-up visits in the outpatient setting. Participants who do not receive the
drug in Phase 1, will have the opportunity to enroll in Phase 2 of the study where everyone
will receive the thyroid hormone treatment.
If this study finds that patients have improved heart function after treatment with thyroid
hormone without unacceptable side effects, this could result in a new treatment for patients
with heart failure.